FT-001 is under clinical development by Frontera Therapeutics and currently in Phase II for Leber Congenital Amaurosis (LCA). According to GlobalData, Phase II drugs for Leber Congenital Amaurosis ...
It is difficult to determine the exact prognosis and specific management of patients with amaurosis fugax in the literature. Fortunately, there are some excellent collaborative groups who have ...